Despite a rethink that saw Cellectis drop its multiple myeloma CAR-T only five months ago, AstraZeneca wants in. The Big Pharma is handing over more than $100 million in upfront cash and equity investment for a 10-candidate deal. The collaboration will use Cellectis’ gene editing tech and manufacturing capacity to develop up to 10 cell and gene therapy products. Source: Fierce Biotech 1/11/2023